| |
 |
|
|
|
CanAg develops and markets immunological reagents and kits for determination of
biochemical markers of disease. The company has a strong track record
in the development of high quality monoclonal antibodies and
laboratory test for improved diagnosis and management of patients with
the most common solid cancers. The growth of the company is a result
of a dynamic research and development program.Canag was acquired by Fujirebio Diagnostics, Inc. in May 2006. (For more information, see link below).
www.canag.se
|
|
| |
|
|
|
